TELO - NASDAQ

Telomir Pharmaceuticals, Inc. Common Stock

TELO·NASDAQ

$1.48

+0.0000%

HealthcareBiotechnology

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.88M

EPS-0.3300

P/E Ratio-4.04

Earnings Date05/12/2026

telo

Total Other Income Expenses Net

Last Annual Value

125.64K

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Telomir Pharmaceuticals, Inc. Common Stock Competitors Analysis of Total Other Income Expenses Net

TELO · NASDAQ

Company	Total Other Income Expenses Net	CAGR 3Y	CAGR 5Y	CAGR 10Y
Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO	125.64K	N/A	N/A	N/A
CEL-SCI Corporation AMEX:CVM	-567.99K	N/A	N/A	N/A
Equillium, Inc. NASDAQ:EQ	1.24M	-11.2%	N/A	N/A
INmune Bio, Inc. NASDAQ:INMB	553.00K	N/A	N/A	N/A
Coeptis Therapeutics, Inc. NASDAQ:COEP	766.31K	50.5%	5.1%	N/A
Century Therapeutics, Inc. NASDAQ:IPSC	5.39M	-22.9%	N/A	N/A
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV	6.21M	-3.2%	N/A	N/A
Mersana Therapeutics, Inc. NASDAQ:MRSN	4.56M	N/A	N/A	43.8%
Estrella Immunopharma, Inc. NASDAQ:ESLA	0.00	N/A	N/A	N/A
OS Therapies Incorporated NYSE:OSTX	-2.07M	N/A	N/A	N/A
Senti Biosciences, Inc. NASDAQ:SNTI	8.25M	-4.0%	N/A	N/A

Telomir Pharmaceuticals, Inc. Common Stock Fair Value Envelope

TELO · NASDAQ

Our analysis suggests that TELO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.48, this represents a potential HIDDEN relative to our calculated worth for Telomir Pharmaceuticals, Inc. Common Stock.

HIDDEN

Intrinsic Value

Current Price: $1.48

Related Guides

Blog Categories

Continue your TELO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.